Pfizer announces additional phase 2/3 data on COVID-19 oral antiviral treatment candidate Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) in reducing risk of hospitalisation or death
Final data from EPIC-HR (n=2,246) confirmed prior results showing Paxlovid reduced risk of hospitalization or death by 89% & 88% (within 3 & 5 days symptom onset, respectively) vs placebo.Data have been shared with FDA as part of ongoing submission for Emergency Use Authorization
Source:
Biospace Inc.
SPS commentary:
PAXLOVID is an investigational SARS-CoV-2 protease inhibitor antiviral therapy. Co-administration with a low dose of ritonavir helps slow the metabolism, or breakdown, of nirmatrelvir in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus.
The European Medicines Agency started a review of Paxlovid in November.